[{"orgOrder":0,"company":"Orca Bio","sponsor":"Orca Bio","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Cell Graft","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Orca Bio","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Orca Bio"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Orca Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Stem Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Orca Bio","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Orca Bio"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-Q","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Orca Bio","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Regulatory T Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Orca Bio","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Orca Bio"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lightspeed Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series D Financing","leadProduct":"TRGFT-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Lightspeed Venture","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/ Lightspeed Venture"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Orca Bio \/ Lyell Immunopharma"}]
Find Clinical Drug Pipeline Developments & Deals by Orca Bio
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target